Elan today said it is retaining three American business units that it believes are value generating and provide opportunities for revenue growth and key technological capabilities
The three units to be retained are NanoSystems, its drug delivery business based in Pennsylvania;
its drug-delivery business and operations in Georgia; and the company's US acute care business, which includes the hospital care products Maxipime and Azactam.
Elan president and chief executive officer Mr Kelly Martin said: "As we enter the final stages of our recovery plan, retaining these profitable businesses gives us strategic flexibility and the opportunity to optimise their value moving forward."
